ELI LILLY & Co (LLY) stock
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3025% above fair value
$1415.55−16.12 (-1.13%)
Close on Nov 17, 2026Market cap $1.33TP/E 45.9Yield 0.44%
Eli Lilly price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Eli Lilly's price to sales ratio was 16.2× on Nov 11, 2026, against 16.3× a year earlier. Over the last 5 years it ranged from 8.0× to 22.7×, with a median of 14.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 16.2× | −0.1 |
| 2025 | Dec 31, 2025 | 16.3× | −0.8 |
| 2024 | Dec 31, 2024 | 17.1× | +0.7 |
| 2023 | Dec 29, 2023 | 16.4× | +5.1 |
| 2022 | Dec 30, 2022 | 11.3× | +2.3 |
| 2021 | Dec 31, 2021 | 9.1× | +2.4 |
| 2020 | Dec 31, 2020 | 6.6× | +0.8 |
| 2019 | Dec 31, 2019 | 5.8× | +0.3 |
| 2018 | Dec 31, 2018 | 5.4× | +1.5 |
| 2017 | Dec 29, 2017 | 4.0× | +0.2 |
| 2016 | Dec 30, 2016 | 3.7× | −0.8 |
| 2015 | Dec 31, 2015 | 4.6× | +1.3 |
| 2014 | Dec 31, 2014 | 3.2× | +0.8 |
| 2013 | Jan 31, 2013 | 2.5× | +0.2 |
| 2012 | Dec 31, 2012 | 2.3× | – |
See a number that looks wrong?